Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

KALA - KALA BIO, Inc.


7.05
-0.120   -1.702%

Share volume: 11,728
Last Updated: 03-07-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.03%

PREVIOUS CLOSE
CHG
CHG%

$7.17
-0.12
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
23%
Profitability 8%
Dept financing 25%
Liquidity 58%
Performance 30%
Company vs Stock growth
vs
Performance
5 Days
-1.67%
1 Month
-35.20%
3 Months
13.53%
6 Months
17.11%
1 Year
-9.85%
2 Year
-54.10%
Key data
Stock price
$7.05
P/E Ratio 
0.00
DAY RANGE
$6.83 - $7.08
EPS 
-$9.71
52 WEEK RANGE
$4.21 - $11.20
52 WEEK CHANGE
-$6.87
MARKET CAP 
26.263 M
YIELD 
N/A
SHARES OUTSTANDING 
4.608 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.71
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$33,809
AVERAGE 30 VOLUME 
$84,249
Company detail
CEO: Mark T. Iwicki
Region: US
Website: kalarx.com
Employees: 30
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Kala Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid.

Recent news